Table 2. Primary Outcome^a.

	Double active	tDCS only	Double sham
HDRS-17 scores at various time points, mean (SD)b
Baseline	21.0 (3.3)	20.8 (3.5)	20.8 (3.3)
Week 2	14.5 (4.4)	14.5 (4.7)	13.4 (5.4)
Week 3	13.0 (5.0)	13.4 (5.3)	13.5 (5.5)
Week 4	13.5 (5.8)	13.1 (5.7)	13.3 (6.4)
Week 6	12.8 (5.0)	12.4 (5.1)	13.0 (6.2)
Response/remission rates at various time points, No. (%)c
Baseline	NA	NA	NA
Week 2	12 (19)/5 (8)	13 (18)/6 (8)	20 (28)/12 (17)
Week 3	21 (33)/10 (16)	21 (30)/9 (13)	23 (32)/9 (12)
Week 4	24 (38)/8 (13)	19 (28)/10 (14)	24 (33)/15 (21)
Week 6	20 (31)/9 (14)	26 (36)/13 (18)	28 (38)/15 (21)
Change in HDRS-17 score per wk, β (95% CI)d	−1.30 (−1.55 to −1.04)	−1.33 (−1.57 to −1.09)	−1.17 (−1.41 to −0.93)

Abbreviations: HDRS-17, Hamilton Depression Rating Scale 17-item version; tDCS, transcranial direct current stimulation.

^a The estimated effect sizes between groups were as follows: double active vs tDCS only (Cohen d, 0.05; 95% CI, −0.48 to 0.58; P = .86), double active vs double sham (Cohen d,−0.20; 95% CI, −0.73 to 0.34; P = .47), and tDCS only vs double sham (Cohen d, −0.25; 95% CI, −0.76 to 0.27; P = .35). Group comparisons represent estimated differences in HDRS-17 change per week between groups.

^b HDRS-17²⁰ scores range from 0-52; minimally significant score, 0-7; remission, ≤7.

^c Response was defined as a ≥50% decrease in baseline HDRS-17 score and remission as an HDRS-17 score ≤7.

^d β Values are model estimations of changes in HDRS-17 scores for 1 week.